Antibodies

14 October 2024

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia

14 October 2024

FDA Approves IMULDOSA® (ustekinumab-srlf), Accord BioPharma’s Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions

12 October 2024

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

12 October 2024

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

11 October 2024

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

11 October 2024

Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption

10 October 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

10 October 2024

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn’s disease and ulcerative colitis

10 October 2024

Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases

9 October 2024

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMAProlia® (denosumab) is indicated to treat certain conditions that lead to high risk for

9 October 2024

Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)

9 October 2024

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

9 October 2024

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma

8 October 2024

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

8 October 2024

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

8 October 2024

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

8 October 2024

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

4 October 2024

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

4 October 2024

Recordati announces agreement to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise

4 October 2024

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders

4 October 2024

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

4 October 2024

Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers

4 October 2024

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

2 October 2024

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

1 October 2024

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

1 October 2024

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

30 September 2024

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

30 September 2024

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)

30 September 2024

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

29 September 2024

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TL1A Inhibitor Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Adalimumab (Humira) Biosimilars Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

GPC3-Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies